VESSL Therapeutics develops cell-based therapies for patients who suffer from cardiovascular and other vascular-related conditions and cannot be treated adequately with existing therapeutic modalities.

Its core technology is based on an integrative approach for the treatment of cardiovascular disease.VESSLs two leading products, MultiGeneAngio and MultiGeneGraft, have been approved by the FDA for clinical studies, and two phase 1/2 clinical trials with MultiGeneAngio have been completed.MultiGeneAngio is a combination of two cell types and two genes, and MultiGeneGraft is the combination of cells, genes, and a synthetic graft.

These two technologies are used in therapies for patients with peripheral artery disease and coronary artery disease, and for patients with renal disease requiring hemodialysis.The companys products are based on the patients own cells, isolated from a short vein segment taken from the patients arm under local anesthesia.

The isolated cells are activated by the insertion of specific genes and then reintroduced to the patient.The FDA has granted an Investigational New Drug (IND) authorization for MultiGeneGraft.